Last reviewed · How we verify
Injectable giomer restoration
Injectable giomer restoration is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Dental cavity restoration, Class III and V caries lesions, Tooth defect restoration.
Injectable giomer restoration provides direct restorative material for dental cavities and tooth defects through a glass-ionomer-based composite formulation.
Injectable giomer restoration is used to treat conditions such as deep caries, caries, and dental caries. The exact mechanism of action of giomer is unknown, but it is used in clinical trials as a treatment for dental restorations.
At a glance
| Generic name | Injectable giomer restoration |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Therapeutic area | Dentistry |
| Phase | FDA-approved |
Mechanism of action
Giomers are hybrid restorative materials that combine the benefits of glass-ionomer cements and composite resins. The injectable formulation allows for minimally invasive delivery into prepared tooth cavities, where it sets to form a durable restoration that bonds to tooth structure and can release fluoride for caries prevention.
Approved indications
- Dental cavity restoration
- Class III and V caries lesions
- Tooth defect restoration
Common side effects
Key clinical trials
- Injection Molding Technique: A Minimally Invasive Management for Enamel Hypoplasia Affecting Permanent Anterior Teeth in Children (PHASE4)
- Clinical Performance of Flowable Giomer Versus Nanofilled Composite in Conservative Occlusal Cavities (NA)
- Clinical Assessment of Giomer Based Technology Versus Smart Bioactive Restoration in Carious Class V Cavities (NA)
- Performance of Bioactive Low Viscosity Composite in Deep Marginal Elevation Restorations (NA)
- Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation (NA)
- Clinical Assessment of Injectable Flowable Composite with Giomer Technology Vs High Viscosity Glass Ionomer Restorations in ART for Cancer Patients (PHASE3)
- Clinical Performance of Two Different Restorative Materials in Restoring Class II Cavities of Primary Molars (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injectable giomer restoration CI brief — competitive landscape report
- Injectable giomer restoration updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Injectable giomer restoration
What is Injectable giomer restoration?
How does Injectable giomer restoration work?
What is Injectable giomer restoration used for?
Who makes Injectable giomer restoration?
What development phase is Injectable giomer restoration in?
Related
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Dentistry
- Indication: Drugs for Dental cavity restoration
- Indication: Drugs for Class III and V caries lesions
- Indication: Drugs for Tooth defect restoration
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing